HomeSBHMY • OTCMKTS
Sino Biopharmaceutical Unsponsored Caymand Islands ADR
$7.75
Jan 15, 12:20:21 AM GMT-5 · USD · OTCMKTS · Disclaimer
US listed security
Previous close
$7.75
Year range
$6.69 - $9.65
Market cap
53.96B HKD
Avg Volume
58.00
CDP Climate Change Score
B
In the news
Financials
Income Statement
Revenue
Net income
(CNY)Jun 2024Y/Y change
Revenue
7.94B11.14%
Operating expense
4.78B10.58%
Net income
1.51B139.69%
Net profit margin
19.01115.78%
Earnings per share
——
EBITDA
1.98B8.88%
Effective tax rate
16.99%—
Total assets
Total liabilities
(CNY)Jun 2024Y/Y change
Cash and short-term investments
13.18B-15.93%
Total assets
66.70B1.62%
Total liabilities
24.58B-15.76%
Total equity
42.12B—
Shares outstanding
18.21B—
Price to book
4.31—
Return on assets
6.50%—
Return on capital
8.37%—
Net change in cash
(CNY)Jun 2024Y/Y change
Net income
1.51B139.69%
Cash from operations
1.54B15.25%
Cash from investing
-1.02B49.91%
Cash from financing
-2.05B-1.42%
Net change in cash
-1.52B43.37%
Free cash flow
1.09B36.59%
About
Sino Biopharmaceutical Limited, shortly Sino Biopharm, is a pharmaceutical conglomerate in China. The Company was listed on the Hong Kong Stock Exchange in 2000 and included in 2013 as a constituent stock of MSCI Global Standard Indices – MSCI China Index, Hang Seng Index in 2018, Hang Seng China Enterprises Index in 2019, and Hang Seng Connect Biotech 50 Index and Hang Seng China 25 Index in 2020. The Group’s principal subsidiaries include: Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Beijing Tide Pharmaceutical Co. Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd. and invoX Pharma Limited. Its products including biopharmaceutical and chemical medicines are used in a host of therapeutic areas, such as tumors, liver diseases, respiratory system diseases and surgery/analgesia. Wikipedia
Founded
2000
Employees
24,437
Search
Clear search
Close search
Google apps
Main menu